Contacts

Covid-19: MedinCell presents positive first results from the clinical trial aiming at validating the safety of continuous administration of Ivermectin

December 17, 2020

Study’s first results presented at the international “Collaborative Workshop – Ivermectin against Covid-19” held on December 15, 16 and 17 at the initiative of MedinCell

No side effects observed with the first two doses in the study, which includes a total of three doses

A first long-acting injectable formulation is ready to enter regulatory development

Session en français

Mardi 19 décembre, 18h30 : Présentation des résultats du premier semestre de l'année fiscale 2023-24

English session

Tuesday, December 19, 6:30 pm: Half-year earnings call (April 1st - September 30th)

Êtes-vous un actionnaire de MedinCell ? / Are you a MedinCell shareholder?
Vous êtes / You are :
This field is for validation purposes and should be left unchanged.

CONTACT

  • This field is for validation purposes and should be left unchanged.